Medical Disclaimer: This article is for educational and informational purposes only and does not constitute individual medical advice, diagnosis, or clinical treatment. Always consult your personal physician or qualified healthcare provider regarding medical conditions, prescription changes, or new health regimens.
Transparency Disclosure: Dibesity features independent, evidence-based medical research. Some articles may contain vetted affiliate links to metabolic wellness products; if you make a purchase, we may earn a modest commission at no extra cost to you.
Introduction
Skin treatment is not one-size-fits-all. A medicine that works well for one person may be unsuitable for a pregnant woman, a young child, a person going through menopause, or someone who has had a stem cell transplant. Dermatologists must weigh benefits and risks for each situation.
This guide draws on five recent publications, including consensus statements, narrative reviews, and a prospective cohort study. It explains what these sources say about special populations and where the evidence is still thin.
What Is Individualized Dermatologic Care?
Individualized care means choosing treatments based on a person’s age, life stage, other health conditions, and medicines. It also means considering how the skin problem affects daily life.
Professional groups increasingly publish guidance that addresses these differences. A 2026 Taiwanese consensus on atopic dermatitis, a chronic itchy inflammatory skin condition, includes special considerations for pregnant, breastfeeding, pediatric, and older patients, as well as patients with active infections or who are due for vaccination [1].
Why Does It Matter?
Many people with skin disease belong to groups that were under-studied in early clinical trials. Children, pregnant people, and older adults are often excluded from research. As a result, doctors sometimes have to extrapolate from limited data.
Life stage can also change how skin disease behaves. Hormonal shifts, immune system changes, and transplant medicines can all alter symptoms and treatment choices.
What Does the Latest Research Show?
Children and Hives
In a single-center prospective cohort study of 210 children with a first episode of acute urticaria (hives), most cases resolved with standard antihistamine treatment. The authors reported complete remission in 95.2% of patients, and 4.8% progressed to chronic urticaria during follow-up [5].
The study found that urticaria lasting more than 7 days and hives triggered by physical stimuli were independent predictors of progression.
Age, atopy, and baseline severity were not associated with progression. Because this is an observational cohort study, these findings show associations, not proof that any factor causes chronic hives [5].
Menopause and the Skin
Menopause can bring skin and hair changes, sometimes before hot flashes become noticeable. These changes are linked to falling estrogen levels and a relative excess of androgens, which are male-type hormones present in all sexes. Common concerns include dry skin, thinning skin, hair loss, new acne, rosacea, and vulvovaginal symptoms [2].
A 2026 review describes management strategies for these problems and notes recent regulatory changes and evolving evidence on topical and systemic estrogen.
The authors flag that some areas remain poorly studied. Dermatologists are encouraged to counsel patients on both the benefits and the uncertainties of hormone therapy [2].
Medication-Related Sexual Side Effects
Sexual dysfunction is an under-recognized side effect of several skin medicines. A 2026 comprehensive review rated the strength of evidence by drug class.
The strongest evidence involves 5-alpha-reductase inhibitors and selective serotonin or serotonin-norepinephrine reuptake inhibitors (SSRIs and SNRIs) [3].
Emerging evidence links spironolactone to female sexual dysfunction, including pain during intercourse and reduced arousal. These effects have not been studied well at dermatologic doses [3].
For isotretinoin, methotrexate, corticosteroids, cyclosporine, and several other drugs, the evidence is limited to small studies, case reports, or trials that did not measure sexual function [3].
Biologic therapies for psoriasis and atopic dermatitis were consistently associated with improved sexual function in the reviewed literature. The authors suggest this may reflect better control of systemic disease rather than a direct drug effect [3].
Transplant Recipients and Skin Graft-versus-Host Disease
After a stem cell transplant, donor immune cells can attack the recipient’s tissues. This is called graft-versus-host disease (GVHD).
The skin is one of the most commonly affected organs. Mild skin disease is often treated with topical corticosteroids, which are anti-inflammatory creams, along with supportive skin care [4].
Moderate to severe disease usually requires systemic corticosteroids, medicines taken by mouth or injection.
Up to 60% of patients may develop steroid-refractory or steroid-resistant disease, meaning the medicine does not work well enough [4].
Newer targeted agents, including ruxolitinib, belumosudil, axatilimab, ibrutinib, and abatacept, are discussed in the review as options chosen according to established algorithms or specific clinical situations [4].
Topical ruxolitinib, phototherapy, and extracorporeal photopheresis may be used as add-on treatments for persistent or localized skin disease [4].
Cell-based therapies, such as mesenchymal stromal cells and regulatory T cells, are described as emerging. They remain investigational and are not standard care [4].
How Does It Work?
Many skin conditions involve an overactive immune system. Immune cells release chemical messengers that drive redness, swelling, and itch.
Targeted treatments aim at specific steps in these pathways rather than suppressing the whole immune system.
Hormone therapy works differently. It replaces or adjusts hormones that influence skin oil production, collagen, and barrier function. Its effects on the skin are still being studied, and benefits vary between people [2].
Some medicines affect sexual function through hormonal or nervous system pathways, although the exact mechanisms are not fully understood for every drug [3].
Who May Benefit?
- Children with hives lasting more than a week or triggered by physical stimuli may need closer follow-up [5].
- Women considering hormone therapy for menopausal skin or hair changes benefit from individualized counseling [2].
- People taking medicines with known sexual side effects may benefit from discussing these risks before starting treatment [3].
- Transplant recipients with steroid-resistant skin GVHD may be considered for alternative systemic treatments through specialist care [4].
Practical Implications
Clinicians should ask about sexual health before starting many dermatologic medicines. Pre-treatment counseling matters because chronic sexual side effects are poorly characterized and have few proven management strategies [3].
For children with acute hives, the cohort data suggest that most cases resolve without extensive testing. Monitoring is still important for those whose symptoms persist [5].
In transplant care, dermatologists often work with transplant teams to balance skin treatment against the risk of weakening the immune system [4].
Risks and Safety Concerns
Every treatment carries risks. Systemic corticosteroids can cause side effects, especially with long use. Targeted immune medicines can affect infection risk, which is why infections and vaccination status are considered in consensus guidance [1,4].
Women are underrepresented in drug safety data for sexual side effects. This gap is important because spironolactone, isotretinoin, and SSRIs or SNRIs are often prescribed to young women [3].
Experimental cell-based therapies for GVHD are not proven standard care and should only be used in research settings or specialized programs [4].
Limitations of Current Research
- None of the reviewed sources were randomized controlled trials or meta-analyses. Most are reviews, consensus statements, or observational studies [1,2,3,4,5].
- This article is based on abstracts. Full texts were not reviewed in detail.
- Evidence on sexual dysfunction and pregnancy is largely small or observational [3].
- The retransplant approach discussed in the field is largely conceptual, with limited direct cohort data [4].
- Many sources are recent, and few have been independently replicated.
Frequently Asked Questions
Can children with hives always be treated without tests?
Not always. In one cohort, most children with a first episode of acute hives recovered with antihistamines and did not need extensive testing [5]. A doctor still decides which tests, if any, are needed for each child.
Is hormone therapy a standard option for menopausal skin changes?
Hormone therapy is discussed as one option, with benefits and limits that vary. The review emphasizes counseling about uncertainties and the role of other treatments [2].
Do skin medicines affect sexual health?
Some do. The strongest evidence involves 5-alpha-reductase inhibitors and SSRIs or SNRIs, while evidence for many other drugs is limited [3].
Are cell therapies available for skin GVHD?
Cell-based therapies such as mesenchymal stromal cells and regulatory T cells are investigational. They are not standard care [4].
Key Takeaways
- Skin treatment should be individualized for age, life stage, and other health conditions [1,2].
- Most acute hives in children resolve quickly, but prolonged symptoms or physical triggers raise the chance of chronic hives [5].
- Sexual side effects of some skin medicines are under-studied, especially in women [3].
- Targeted systemic treatments for transplant-related skin disease are expanding, while cell therapies remain experimental [4].
- Many findings come from observational data, so uncertainty remains high [2,3,5].
Medical Disclaimer: This article is for educational purposes only and does not replace professional medical advice. Consult a qualified healthcare professional before making treatment decisions.
References
- Taiwanese Dermatological Association consensus for the management of atopic dermatitis: A 2024 update.. DOI: https://doi.org/10.1016/j.jfma.2026.11.012
- Cutaneous Manifestations of the Menopausal Transition – Part 2: Hormonal Frameworks and Management of Skin and Hair Concerns.. DOI: https://doi.org/10.1016/j.jaad.2026.11.027
- Sexual Dysfunction Associated with Dermatologic Medications – A Comprehensive Review.. DOI: https://doi.org/10.1016/j.clindermatol.2026.11.026
- A Review of Modern Therapies and New Innovations in the Treatment of Cutaneous Graft-versus-Host Disease.. DOI: https://doi.org/10.1007/s13555-026-01919-3
- Clinical Follow-Up, Etiology, and Predictors of Progression to Chronic Urticaria in Children with Acute Urticaria: A Guideline-Based Study.. DOI: https://doi.org/10.1177/2151321×261470202

